Mouse Anti-KLK2 Recombinant Antibody (CBT4076) (V2LY-0625-LY1776)

Khosroabadi, G., & Yousefnia, S. (2023). Mechanistic and Diagnostic Roles of Kallikrein Related Peptidases 2 (KLK2) in Prostate Cancer. Personalized Medicine Journal, 8(28), 5-12.

Candilejo, I. M., Herranz, L. P., de Spéville, B. D., Diaz-Tejeiro, C., Nieto-Jimenez, C., Sanvicente, A., ... & Fernandez, A. O. (2023). 40P Bioinformatic evaluation of the transcriptomic and immunologic profile of prostate tumors with high expression of kallikrein-2. Annals of Oncology, 34, S199.

Bonk, S., Kluth, M., Jansen, K., Hube‐Magg, C., Makrypidi‐Fraune, G., Höflmayer, D., ... & Dum, D. (2020). Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG‐negative prostate cancer. The Prostate, 80(13), 1097-1107.

Adamopoulos, P. G., Kontos, C. K., & Scorilas, A. (2019). Discovery of novel transcripts of the human tissue kallikrein (KLK1) and kallikrein-related peptidase 2 (KLK2) in human cancer cells, exploiting Next-Generation Sequencing technology. Genomics, 111(4), 642-652.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols